The October 20, 2020, article by DiSilvestro et al entitled “Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial” (J Clin Oncol 10.1200/JCO.20.00799) was published with errors.
In Table 1:
At baseline in the intent-to-treat population, the number (%) of patients with clinical complete response after platinum-based chemotherapy should have read 189 (73) in the olaparib group, rather than 213 (82), and 101 (77) in the placebo group, rather than 107 (82) (reported per electronic case report form to be consistent with the progression-free survival analysis, instead of per randomization). The number (%) of patients with partial response should have read 71 (27) in the olaparib group, rather than 47 (18), and 30 (23) in the placebo group, rather than 24 (18).
In the subgroup of patients with a BRCA2 mutation who received placebo, the number (%) of patients with unknown residual disease status after upfront surgery should have read 1 (5), rather than 1 (3).
In Figure 2A, in the subgroup of patients who underwent interval surgery and received placebo, the number of events/total number of patients (%) should have read 35/43 (81), rather than 35/42 (81).
In Figure 2C, in the subgroup of patients with stage III disease who underwent upfront surgery, had no gross residual disease, and received placebo, the number of events/total number of patients (%) should have read 38/58 (66), rather than 58/131 (66).
This has been corrected as of March 25, 2021. The authors apologize for the errors.